M. A. Bookman

740 total citations
15 papers, 583 citations indexed

About

M. A. Bookman is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, M. A. Bookman has authored 15 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Reproductive Medicine and 3 papers in Molecular Biology. Recurrent topics in M. A. Bookman's work include Ovarian cancer diagnosis and treatment (6 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer therapeutics and mechanisms (2 papers). M. A. Bookman is often cited by papers focused on Ovarian cancer diagnosis and treatment (6 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer therapeutics and mechanisms (2 papers). M. A. Bookman collaborates with scholars based in United States, Czechia and Italy. M. A. Bookman's co-authors include Andrea Alberto Lissoni, Anderley Gordon, Jutta Krebs, Giorgio Bolis, Scott Z. Fields, Henric Malmström, Robert F. Ozols, Dwight D. Kloth, Szymon Smoliński and Benjamin E. Greer and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

In The Last Decade

M. A. Bookman

14 papers receiving 564 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. A. Bookman United States	9	316	237	217	111	102	15	583
Delaloye Jf Switzerland	3	735 2.3×	346 1.5×	422 1.9×	281 2.5×	114 1.1×	8	935
A. Hay United Kingdom	6	505 1.6×	274 1.2×	302 1.4×	207 1.9×	99 1.0×	9	693
C.A.M. de Swart Netherlands	5	290 0.9×	161 0.7×	205 0.9×	102 0.9×	50 0.5×	8	430
Tomoyuki Yoshikawa Japan	13	150 0.5×	206 0.9×	121 0.6×	103 0.9×	172 1.7×	50	522
Sally Baron‐Hay Australia	14	220 0.7×	388 1.6×	82 0.4×	148 1.3×	237 2.3×	48	775
Moon‐Hong Kim South Korea	17	274 0.9×	167 0.7×	210 1.0×	505 4.5×	117 1.1×	30	841
Morikazu Miyamoto Japan	16	301 1.0×	209 0.9×	128 0.6×	291 2.6×	249 2.4×	82	857
Youn Choi Park United States	8	305 1.0×	548 2.3×	162 0.7×	103 0.9×	125 1.2×	13	1.0k
Christine Gennigens Belgium	13	95 0.3×	171 0.7×	77 0.4×	153 1.4×	146 1.4×	55	530
Małgorzata Fuksiewicz Poland	14	68 0.2×	321 1.4×	76 0.4×	79 0.7×	170 1.7×	42	620

Countries citing papers authored by M. A. Bookman

Since Specialization

Citations

This map shows the geographic impact of M. A. Bookman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. A. Bookman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. A. Bookman more than expected).

Fields of papers citing papers by M. A. Bookman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. A. Bookman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. A. Bookman. The network helps show where M. A. Bookman may publish in the future.

Co-authorship network of co-authors of M. A. Bookman

This figure shows the co-authorship network connecting the top 25 collaborators of M. A. Bookman. A scholar is included among the top collaborators of M. A. Bookman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. A. Bookman. M. A. Bookman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Burger, Robert A., M F Brady, Joon Haeng Rhee, et al.. (2011). Independent radiologic review of GOG218, a phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian (EOC), primary peritoneal (PPC) or Fallopian tube cancer (FTC).. Journal of Clinical Oncology. 29(15_suppl). 5023–5023. 4 indexed citations

Tew, William P., James Java, Andrew Menzin, et al.. (2010). Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182).. Journal of Clinical Oncology. 28(15_suppl). 5030–5030. 16 indexed citations

Tew, William P., et al.. (2009). O8 Treatment outcomes for older women with advanced ovarian cancer: results from a phase III clinical trial (GOG182). Critical Reviews in Oncology/Hematology. 72(1). S17–S17.

Dilts, David M., et al.. (2008). Accrual to clinical trials at selected comprehensive cancer centers. Journal of Clinical Oncology. 26(15_suppl). 6543–6543. 4 indexed citations

Krivak, Thomas C., Kathleen M. Darcy, Chunqiao Tian, et al.. (2008). Relationship between ERCC1 polymorphisms, disease progression, and survivalin GOG0182, a Gynecologic Oncology Group phase III trial of platinum-based chemotherapy in women with advanced stage epithelial ovarian or primary peritoneal cancer. Journal of Clinical Oncology. 26(15_suppl). 5540–5540. 2 indexed citations

Bookman, M. A.. (2005). Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. International Journal of Gynecological Cancer. 15. 12–17. 5 indexed citations

Lepisto, Eva M., Joyce C. Niland, Richard L. Theriault, et al.. (2005). The addition of taxanes to adjuvant chemotherapy for lymph node positive (N+) early breast cancer (BC): Institutional practice variation in the National Comprehensive Cancer Network (NCCN). Journal of Clinical Oncology. 23(16_suppl). 654–654. 1 indexed citations

Gallo, James M., Paolo Vicini, Shaolan Li, et al.. (2004). Pharmacokinetic Model-Predicted Anticancer Drug Concentrations in Human Tumors. Clinical Cancer Research. 10(23). 8048–8058. 41 indexed citations

Bookman, M. A., Benjamin E. Greer, & Robert F. Ozols. (2003). Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5. International Journal of Gynecological Cancer. 13(s2). 149–155. 19 indexed citations

10.

Bookman, M. A., Benjamin E. Greer, & Robert F. Ozols. (2003). Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOGO 182-ICON5. International Journal of Gynecological Cancer. 13(6). 735–740. 20 indexed citations

11.

Bookman, M. A., Henric Malmström, Giorgio Bolis, et al.. (1998). Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.. Journal of Clinical Oncology. 16(10). 3345–3352. 281 indexed citations

12.

Bookman, M. A., et al.. (1997). Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Annals of Oncology. 8(6). 611–614. 92 indexed citations

13.

Bookman, M. A., et al.. (1997). Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.. PubMed. 24(6 Suppl 19). S19–13. 28 indexed citations

14.

Reed, E, John E. Janik, M. A. Bookman, et al.. (1993). High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.. Journal of Clinical Oncology. 11(11). 2118–2126. 18 indexed citations

15.

Bookman, M. A., Pilar Lardelli, Elaine S. Jaffe, P L Duffey, & Dan L. Longo. (1990). Lymphocytic Lymphoma of Intermediate Differentiation: Morphologic, Immunophenotypic, and Prognostic Factors. JNCI Journal of the National Cancer Institute. 82(9). 742–748. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact